Kai Lin
About
Kai Lin is from Boston, Massachusetts, United States. Kai works in the following industries: "Pharmaceutical Manufacturing". Kai is currently Vice President, Virology at Atea Pharmaceuticals, Inc, located in Boston, Massachusetts, United States. In Kai's previous role as a Senior Director, Head of Virology at Enanta Pharmaceuticals, Kai worked in Watertown, Massachusetts until Nov 2020. Prior to joining Enanta Pharmaceuticals, Kai was a Executive Director, Biology and Translational Science at Idenix Pharmaceuticals, Inc. (acquired by Merck & Co.) and held the position of Executive Director, Biology and Translational Science at Cambridge, Massachusetts. Prior to that, Kai was a Director of Biology at Permeon Biologics, Inc., based in Cambridge, Massachusetts from Jun 2012 to May 2014. Kai started working as Senior Investigator II, Group Head (2006-2012), Lab Head (2004-2006) at Novartis, Cambridge, Massachusetts, USA in Cambridge, Massachusetts, United States in May 2004. From Jan 2000 to May 2004, Kai was Staff Investigator (2002-2004), Investigator (2000-2002) at Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts, USA. Prior to that, Kai was a Postdoctoral Fellow at University of Pennsylvania, based in Philadelphia, Pennsylvania, United States from May 1999 to Jan 2000.
If you’re looking for Kai Lin's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Kai Lin's current jobs
SARS-CoV-2 (COVID-19), Dengue, RSV
Kai Lin's past jobs
RSV, HBV, SARS-CoV-2 (COVID-19)
Virology, oncology
Antibody-drug conjugates (ADC), protein therapeutics Oncology, rare diseases
• Built and managed a research group of 14 PhD and non-PhD scientists • Initiated and led five drug discovery programs involving multi-disciplinary teams • Delivered three IND filings, including one progressed into Phase III clinical trials • Closely interacted with health authorities (FDA, EMA and sFDA) and KOLs • Played a major role in developing portfolio and evaluating in-licensing opportunities • Established and managed multiple external partnerships and academic collaborations
• Responsible for biology support for the HCV protease program - a key contributor to the discovery of Incivek/Telaprevir/VX-950, the first approved antiviral drug for HCV • Involved in multiple kinase programs for oncology indications: established in vitro and cell-based kinase assays and performed signal transduction and cell cycle analysis • Provided preclinical support for the development of IMPDH inhibitors
• Designed and optimized novel in vitro assays for high-throughput screening of natural products in collaboration with National Cancer Institute